Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil E Martin

Showing results (51-60 of 123) with videos related to

Pageof 13
Sort By:
Brachytherapy|April 19, 2015
Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancerVinayak Muralidhar, Brandon A Mahal, David R Ziehr, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 8, 2019
Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen LevelVinayak Muralidhar, Paul L Nguyen, Brandon A Mahal, et al.
Urologic Oncology|October 19, 2015
Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012Michelle D Nezolosky, Kathryn T Dinh, Vinayak Muralidhar, et al.
The Prostate|October 16, 2015
Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUCTravis A Gerke, Neil E Martin, Zhihu Ding, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Cancer-specific outcomes among young adults without health insuranceAyal A Aizer, Benjamin Falit, Mallika L Mendu, et al.
Cancer|March 13, 2016
National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base studyBrandon A Mahal, Yu-Wei Chen, Jason A Efstathiou, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 14, 2015
Cost implications and complications of overtreatment of low-risk prostate cancer in the United StatesAyal A Aizer, Xiangmei Gu, Ming-Hui Chen, et al.
Practical Radiation Oncology|August 25, 2019
Minimum Data Elements for Radiation Oncology: An American Society for Radiation Oncology Consensus PaperJames A Hayman, Andre Dekker, Mary Feng, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 16, 2026
Renal Impairment and Late Toxicities Comparing Contemporary Chemotherapy Regimens for Testicular Cancer in a Real-World SettingSarah L Kerns, Paul C Dinh, Patrick O Monahan, et al.
Molecular Cancer Research : MCR|July 1, 2015
Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate CancerNeil E Martin, Travis Gerke, Jennifer A Sinnott, et al.
Pageof 13

Showing results (51-60 of 123) with videos related to

Sort By:
Pageof 13
Brachytherapy|April 19, 2015
Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancerVinayak Muralidhar, Brandon A Mahal, David R Ziehr, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 8, 2019
Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen LevelVinayak Muralidhar, Paul L Nguyen, Brandon A Mahal, et al.
Urologic Oncology|October 19, 2015
Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012Michelle D Nezolosky, Kathryn T Dinh, Vinayak Muralidhar, et al.
The Prostate|October 16, 2015
Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUCTravis A Gerke, Neil E Martin, Zhihu Ding, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Cancer-specific outcomes among young adults without health insuranceAyal A Aizer, Benjamin Falit, Mallika L Mendu, et al.
Cancer|March 13, 2016
National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base studyBrandon A Mahal, Yu-Wei Chen, Jason A Efstathiou, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 14, 2015
Cost implications and complications of overtreatment of low-risk prostate cancer in the United StatesAyal A Aizer, Xiangmei Gu, Ming-Hui Chen, et al.
Practical Radiation Oncology|August 25, 2019
Minimum Data Elements for Radiation Oncology: An American Society for Radiation Oncology Consensus PaperJames A Hayman, Andre Dekker, Mary Feng, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 16, 2026
Renal Impairment and Late Toxicities Comparing Contemporary Chemotherapy Regimens for Testicular Cancer in a Real-World SettingSarah L Kerns, Paul C Dinh, Patrick O Monahan, et al.
Molecular Cancer Research : MCR|July 1, 2015
Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate CancerNeil E Martin, Travis Gerke, Jennifer A Sinnott, et al.
Pageof 13